Diagnostic and Prognostic Value of Circulating Tumor Cells in Head and Neck Squamous Cell Carcinoma: A systematic review and meta-analysis

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Wu, Xiang Lei ^a,b,c   Tu, Qian ^b,c   Faure, Gilbert ^b,c   Gallet, Patrice ^c   Kohler, Chantal ^c   Bittencourt, Marcelo De Carvalho ^b,c  

^a WUHAN UNIVERSITY   (China)

^b UNIVERSITÉ DE LORRAINE   (France)

^c UNIVERSITY HOSPITAL OF NANCY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR MARKER;

CANCER STAGING; CARCINOMA, SQUAMOUS CELL; FLOW CYTOMETRY; HEAD AND NECK NEOPLASMS; HUMAN; META ANALYSIS; METASTASIS; MORTALITY; ODDS RATIO; PATHOLOGY; POLYMERASE CHAIN REACTION; PROCEDURES; PROGNOSIS; REPRODUCIBILITY; TUMOR EMBOLISM;

BIOMARKERS, TUMOR; CARCINOMA, SQUAMOUS CELL; FLOW CYTOMETRY; HEAD AND NECK NEOPLASMS; HUMANS; NEOPLASM METASTASIS; NEOPLASM STAGING; NEOPLASTIC CELLS, CIRCULATING; ODDS RATIO; POLYMERASE CHAIN REACTION; PROGNOSIS; REPRODUCIBILITY OF RESULTS;

EID: 84957602545     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep20210     Document Type: Article

References (77)

1. Pantel, K. & Alix-Panabieres, C. Circulating tumour cells in cancer patients: challenges and perspectives. Trends Mol Med. 16, 398-406 (2010).
2. Klein, C. A. Parallel progression of primary tumours and metastases. Nat Rev Cancer. 9, 302-312 (2009).
3. Green, S., Benedetti, J., Smith, A. et al. Clinical trials in oncology. CRC press, 2012. EMT and dissemination precede pancreatic tumor formation. Cell. 148, 349-361 (2012).
4. Alix-Panabieres, C. & Pantel, K. Circulating tumor cells: liquid biopsy of cancer. Clinl Chem. 59, 110-118 (2013).
5. Heitzer, E., Auer, M., Ulz, P., Geigl, J. B. & Speicher, M. R. Circulating tumor cells and DNA as liquid biopsies. Genome Med. 5, 73 (2013).
6. Cohen, S. J. et al. Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J Clin Oncol. 26, 3213-3221 (2008).
7. Cristofanilli, M. et al. Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer. J Clin Oncol. 1420-1430 (2005).
8. Danila, D. C. et al. Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancer. Clin Cancer Res. 13, 7053-7058 (2007).
9. Siegel, R. L., Miller, K. D. & Jemal, A. Cancer Statistics. 2015. CA. 65, 5-29 (2015).
10. Gath, H. J. & Brakenhoff, R. H. Minimal residual disease in head and neck cancer. Cancer Metastasis Rev. 18, 109-126 (1999).
11. Mocellin, S., Keilholz, U., Rossi, C. R. & Nitti, D. Circulating tumor cells: the 'leukemic phase' of solid cancers. Trends Mol Med. 12, 130-139 (2006).
12. Zamora, J., Abraira, V., Muriel, A., Khan, K. & Coomarasamy, A. Meta-DiSc: a software for meta-analysis of test accuracy data. BMC Med Res Methodol. 6, 31 (2006).
13. Higgins, J. P., Thompson, S. G., Deeks, J. J. & Altman, D. G. Measuring inconsistency in meta-analyses. Bmj. 327, 557-560 (2003).
14. Parmar, M. K., Torri, V. & Stewart, L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med. 17, 2815-2834 (1998).
15. Tierney, J. F., Stewart, L. A., Ghersi, D., Burdett, S. & Sydes, M. R. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 8, 16 (2007).
16. Bonequi, P., Meneses-Gonzalez, F., Correa, P., Rabkin, C. S. & Camargo, M. C. Risk factors for gastric cancer in Latin America: a meta-analysis. Cancer Causes Control. 217-231 (2013).
17. Dong, J. Y., Zhang, Y. H., Tong, J. & Qin, L. Q. Depression and risk of stroke: a meta-analysis of prospective studies. Stroke. 43, 32-37 (2012).
18. Higgins, J., Thompson, S., Deeks, J. & Altman, D. Statistical heterogeneity in systematic reviews of clinical trials: a critical appraisal of guidelines and practice. J Health Serv Res Policy. 7, 51-61 (2002).
19. DerSimonian, R. & Laird, N. Meta-analysis in clinical trials. Control Clin Trials. 7, 177-188 (1986).
20. Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G. & Group, P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 151, 264-269 (2009).
21. Brakenhoff, R. H. et al. Sensitive detection of squamous cells in bone marrow and blood of head and neck cancer patients by E48 reverse transcriptase-polymerase chain reaction. Clin Cancer Res. 5, 725-732 (1999).
22. Kao, R. H. & Huang, L. C. High false-positive rate of cytokeratin-19 in detecting circulating tumor cells for nasopharyngeal carcinoma. Chang Gung Med J. 25, 238-244 (2002).
23. Nichols, A. C. et al. Detection of circulating tumor cells in advanced head and neck cancer using the CellSearch system. Head Neck. 34, 1440-1444 (2012).
24. Tinhofer, I., Hristozova, T., Stromberger, C., Keilhoiz, U. & Budach, V. Monitoring of circulating tumor cells and their expression of EGFR/phospho-EGFR during combined radiotherapy regimens in locally advanced squamous cell carcinoma of the head and neck. Int J Radiat Oncol Biol Phys. 83, e685-690 (2012).
25. Hristozova, T., Konschak, R., Budach, V. & Tinhofer, I. A simple multicolor flow cytometry protocol for detection and molecular characterization of circulating tumor cells in epithelial cancers. Cytom Part A. 81, 489-495 (2012).
26. Bozec, A. et al. Significance of circulating tumor cell detection using the CellSearch system in patients with locally advanced head and neck squamous cell carcinoma. Eur Arch Oto-Rhino-L. 270, 2745-2749 (2013).
27. Lin, H. C. et al. A negative selection system PowerMag for effective leukocyte depletion and enhanced detection of EpCAM positive and negative circulating tumor cells. Clin Chim Acta. 419, 77-84 (2013).
28. Partridge, M. et al. Detection of rare disseminated tumor cells identifies head and neck cancer patients at risk of treatment failure. Clin Cancer Res. 9, 5287-5294 (2003).
29. Wang, X. et al. Detection of circulating tumor cells in human peripheral blood using surface-enhanced Raman scattering nanoparticles. Cancer Res. 71, 1526-1532 (2011).
30. Buglione, M. et al. Circulating tumour cells in locally advanced head and neck cancer: preliminary report about their possible role in predicting response to non-surgical treatment and survival. Eur J Cancer. 48, 3019-3026 (2012).
31. Balasubramanian, P. et al. Multiparameter analysis, including EMT markers, on negatively enriched blood samples from patients with squamous cell carcinoma of the head and neck. PloS One. 7, e42048 (2012).
32. Grisanti, S. et al. Circulating tumor cells in patients with recurrent or metastatic head and neck carcinoma: prognostic and predictive significance. PloS One. 9, e103918 (2014).
33. Tinhofer, I. et al. Detection of circulating tumor cells for prediction of recurrence after adjuvant chemoradiation in locally advanced squamous cell carcinoma of the head and neck. Ann Oncol. (2014).
34. Hsieh, J. C. et al. Prognostic value of circulating tumor cells with podoplanin expression in patients with locally advanced or metastatic head and neck squamous cell carcinoma. Head Neck. 37, 1448-1455 (2015).
35. Yang, L. et al. Optimization of an enrichment process for circulating tumor cells from the blood of head and neck cancer patients through depletion of normal cells. Biotechnol Bioeng. 102, 521-534 (2009).
36. Hristozova, T. et al. The presence of circulating tumor cells (CTCs) correlates with lymph node metastasis in nonresectable squamous cell carcinoma of the head and neck region (SCCHN). Ann Oncol. 22, 1878-1885 (2011).
37. Wirtschafter, A. et al. Micrometastatic tumor detection in patients with head and neck cancer: a preliminary report. Arch Otolaryngol Head Neck Surg. 128, 40-43 (2002).
38. Lin, J. C., Chen, K. Y., Wang, W. Y., Jan, J. S. & Wei, Y. H. PCR detection of circulating tumor cells in nasopharyngeal carcinoma patients with distant metastasis: effect of enzyme and sampling. Head Neck. 24, 591-596 (2002).
39. Winter, S. C. et al. Long term survival following the detection of circulating tumour cells in head and neck squamous cell carcinoma. BMC Cancer. 9, 424 (2009).
40. Jatana, K. R. et al. Significance of circulating tumor cells in patients with squamous cell carcinoma of the head and neck: initial results. Arch Otolaryngol Head Neck Surg. 136, 1274-1279 (2010).
41. Weller, P. et al. Detection of circulating tumor cell subpopulations in patients with head and neck squamous cell carcinoma (HNSCC). PloS One. 9, e113706 (2014).
42. Grobe, A. et al. Prognostic relevance of circulating tumor cells in blood and disseminated tumor cells in bone marrow of patients with squamous cell carcinoma of the oral cavity. Clin Cancer Res. 20, 425-433 (2014).
43. R, A. T. A case of cancer in which cells similar to those in the tumours were seen in the blood after death. Aust Med J. 14, 146-149 (1869).
44. Fidler, I. J. The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nature reviews. Cancer. 3, 453-458 (2003).
45. Scher, H. I. et al. Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data. Lancet Oncol. 10, 233-239 (2009).
46. Hayes, D. F. & Smerage, J. Is there a role for circulating tumor cells in the management of breast cancer? Clin Cancer Res. 14, 3646-3650 (2008).
47. Tanaka, F. et al. Circulating tumor cell as a diagnostic marker in primary lung cancer. Clin Cancer Res. 15, 6980-6986 (2009).
48. Wang, Z., Cui, K., Xue, Y., Tong, F. & Li, S. Prognostic value of circulating tumor cells in patients with squamous cell carcinoma of the head and neck: a systematic review and meta-analysis. Med Oncol. 32, 164 (2015).
49. Kamangar, F., Dores, G. M. & Anderson, W. F. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol. 24, 2137-2150 (2006).
50. Forastiere, A., Koch, W., Trotti, A. & Sidransky, D. Head and neck cancer. N Engl J Med. 345, 1890-1900 (2001).
51. Shah, J. P., Candela, F. C. & Poddar, A. K. The patterns of cervical lymph node metastases from squamous carcinoma of the oral cavity. Cancer. 66, 109-113 (1990).
52. Kuriakose, M. A. & Trivedi, N. P. Sentinel node biopsy in head and neck squamous cell carcinoma. Curr Opin Otolaryngol Head Neck Surg. 17, 100-110 (2009).
53. Leemans, C. R., Tiwari, R., Nauta, J. J., van der Waal, I. & Snow, G. B. Recurrence at the primary site in head and neck cancer and the significance of neck lymph node metastases as a prognostic factor. Cancer. 73, 187-190 (1994).
54. Beije, N., Jager, A. & Sleijfer, S. Circulating tumor cell enumeration by the CellSearch system: The clinician's guide to breast cancer treatment? Cancer Treat Rev. 41, 144-150 (2015).
55. Resel Folkersma, L., San Jose Manso, L., Galante Romo, I., Moreno Sierra, J. & Olivier Gomez, C. Prognostic significance of circulating tumor cell count in patients with metastatic hormone-sensitive prostate cancer. Urology. 80, 1328-1332 (2012).
56. Onstenk, W. et al. Improved Circulating Tumor Cell Detection by a Combined EpCAM and MCAM CellSearch Enrichment Approach in Patients with Breast Cancer Undergoing Neoadjuvant Chemotherapy. Mol Cancer Ther. 14, 821-827 (2014).
57. Allen, J. E. et al. Apoptotic circulating tumor cells (CTCs) in the peripheral blood of metastatic colorectal cancer patients are associated with liver metastasis but not CTCs. Oncotarget. 5, 1753-1760 (2014).
58. Loh, J. et al. Circulating tumor cell detection in high-risk non-metastatic prostate cancer. J Cancer Res Clin Oncol. 140, 2157-2162 (2014).
59. Hofman, V. et al. Detection of circulating tumor cells as a prognostic factor in patients undergoing radical surgery for non-small-cell lung carcinoma: comparison of the efficacy of the CellSearch Assay and the isolation by size of epithelial tumor cell method. Int J Caner. 129, 1651-1660 (2011).
60. Wendel, M. et al. Fluid biopsy for circulating tumor cell identification in patients with early-and late-stage non-small cell lung cancer: a glimpse into lung cancer biology. Phys Biol. 9, 016005 (2012).
61. He, S., Li, P., Chen, X. & Yu, Z. Fluid biopsy for circulating tumor cells in an occult ovarian cancer patient exhibiting bilateral supraclavicular lymph node metastases: A case report. Oncol Lett. 6, 448-452 (2013).
62. Riethdorf, S. et al. Detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer: a validation study of the CellSearch system. Clin Cancer Res. 13, 920-928 (2007).
63. Janssen Diagnostics, L. CELLSEARCH® Circulating Tumor Cell Kit (Epithelial) Instructions for Use.
64. Went, P. T. et al. Frequent EpCam protein expression in human carcinomas. Hum Pathol. 35, 122-128 (2004).
65. Takes, R. P. et al. Expression of genetic markers in lymph node metastases compared with their primary tumours in head and neck cancer. J Pathol. 194, 298-302 (2001).
66. Mego, M. et al. Characterization of metastatic breast cancer patients with nondetectable circulating tumor cells. Int J Caner. 129, 417-423 (2011).
67. Konigsberg, R. et al. Detection of EpCAM positive and negative circulating tumor cells in metastatic breast cancer patients. Acta Oncol. 50, 700-710 (2011).
68. Gorges, T. M. et al. Circulating tumour cells escape from EpCAM-based detection due to epithelial-to-mesenchymal transition. BMC Cancer. 12, 178 (2012).
69. Mostert, B. et al. CD49f-based selection of circulating tumor cells (CTCs) improves detection across breast cancer subtypes. Cancer Lett. 319, 49-55 (2012).
70. Pecot, C. V. et al. A novel platform for detection of CK+ and CK- CTCs. Cancer Discov. 1, 580-586 (2011).
71. Raimondi, C. et al. Epithelial-mesenchymal transition and stemness features in circulating tumor cells from breast cancer patients. Breast Cancer Res Treat. 130, 449-455 (2011).
72. Balm, A. J., Hageman, P. C., van Doornewaard, M. H., Groeneveld, E. M. & Ivanyi, D. Cytokeratin 18 expression in squamous cell carcinoma of the head and neck. Eur Arch Otorhinolaryngol. 253, 227-233 (1996).
73. Hudis, C. A. et al. Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system. J Clin Oncol. 25, 2127-2132 (2007).
74. Green, S., Benedetti, J., Smith, A. et al. Clinical trials in oncology. CRC press (2012).
75. Koutsilieris, M., Lembessis, P., Luu-The, V. & Sourla, A. Repetitive and site-specific molecular staging of prostate cancer using nested reverse transcriptase polymerase chain reaction for prostate specific antigen and prostate specific membrane antigen. Clin Exp Metastasis. 17, 823-830 (1999).
76. Sawabata, N. et al. Circulating tumor cells in peripheral blood caused by surgical manipulation of non-small-cell lung cancer: pilot study using an immunocytology method. Gen Thorac Cardiovasc Surg. 55, 189-192 (2007).
77. Lembessis, P. et al. Combined androgen blockade therapy can convert RT-PCR detection of prostate-specific antigen (PSA) and prostate-specific membrane antigen (PSMA) transcripts from positive to negative in the peripheral blood of patients with clinically localized prostate cancer and increase biochemical failure-free survival after curative therapy. Clin Chem Lab Med. 45, 1488-1494, (2007).